Skip to main content
Uncategorized

Advancell celebrates an ADME-Tox conference that draws together the most important speakers from the pharma and biotech industries

By 15 de June de 2010November 18th, 2020No Comments
< Back to news
 15.06.2010

Advancell celebrates an ADME-Tox conference that draws together the most important speakers from the pharma and biotech industries

The biotech Advancell –based at the Barcelona Science Park- is celebrating two conferences which will draw together nationally and internationally renowned scientific speakers today in Barcelona, at the R+D+I Towers Building of the PCB, and next Wednesday at the NH Eurobuilding Hotel of Madrid. Over a hundred people from participating companies from the pharmaceutical industry, the biotech sector and research centers will be attending

The objective of this conference, organized by Advancell, is to bring together renowned scientists from the academic world and from the pharmaceutical and biotech industry with the aim of sharing ADME-Tox knowledge in terms of preclinical experimentation, innovation and regulation. Notable speakers include Edmund Hoppe, the R+D Senior Scientist at the Institute of Drug Metabolism and Pharmacokinetics of Merck Serono; José Vicente Castell, professor of Biochemistry at the School of Medicine of the University of Valencia; Hinnerk Boriss, CEO of SOVICELL; Nicolá Fabre, senior researcher of Preclinical Development at NOSCIRA; Joan Albert Vericat, director of the Department of Preclinical Development at NOSCIRA; María Jesús Zurbano, director of R+D at Advancell Alternative Testing; Imma Pascual, director of Advancell Alternative Testing; Maya Vilà, senior researcher at Advancell Alternative Testing, and Lourdes Gombau, Senior researcher of ADME-Tox at Advancell Alternative Testing

In addition, Advancell held the successful conference “In Vitro Solutions for demands in Dermocosmetics” last week, an event to which leading cosmetic and dermocosmetic companies attended. Some of the main topics discussed in this conference were new European regulations for cosmetic products and the truths and myths concerning the application of stem cells in cosmetics.

Advancell is a biotech company that uses its own technology and continuous innovation to respond to health- and wellbeing-related needs by providing efficient and added value products and services. The company thrives from findings in the academic setting in order to improve and develop them in the market. The company is divided into three business units: Advancell Therapeutics, which focuses its activity on the development of innovative drugs up to their clinical concept testing phase by means of the research of new applications for known molecules; Advancell Alternative Testing, which uses cell-based in vitro methods to predict the efficacy, safety and the mechanism of actions of molecules that are under development, and Advancell Nanosystems, which uses nanomedicine to treat and prevent diseases.

Advancell’s business model enables a considerable reduction of costs, risks and the time needed to develop the drug. Its projects in clinical phase focus on nanomedicines for the treatment of psoriasis (in collaboration with the ISDIN), on the development of a new orphan drug for Chronic Lymphocytic Leukemia and on a topical formulation for the treatment of Plantar Palmar Erythrodysesthesia (ATH008). In addition, “ready to use” cell reactives developed by Advancell Alternative Testing are European leaders in their specialty.

The company is based at the Barcelona Science Park and has research centers at the University of Santiago de Compostela and in the La Fe Hospital of Valencia.